BUY Mankind Pharma Limited — Gaurang Shah, Geojit Investments
byGaurang Shah, Geojit InvestmentsHorizon: 1 year11 Sept 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Elara initiates coverage on Alkem, Eris, IPCA and Mankind. Check ratings and targets
NewsEt-Markets·28 Aug · 2w ago
4 other SEBI-registered advisors have active long-term BUY calls on this stock
Advisor consensus · same horizon·27 Aug · 2w ago
Mankind Pharma inks exclusive deal for two insulin analogues in India
NewsCnbc-Tv18·20 Aug · 3w ago
Mankind Pharma has entered into an exclusive in-licensing agreement for Insulin Degludec and its combination for the Indian market. This strategic move aims to expand the company's product portfolio i
NSE · Press Release·20 Aug · 3w ago
Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd. for Insulin Degludec and Insulin Degludec + Aspart Combination in In
BSE · Company Update·20 Aug · 3w ago
Mankind Pharma Limited's Board approved the integration of its wholly owned subsidiary, Bharat Serums and Vaccines Limited, into the company via voluntary liquidation.
NSE · Outcome of Board Meeting·26 Aug · 2w ago
Mankind Pharma completes security realignment and releases pledged shares worth 38.68% of Bharat Serums and Vaccines' equity
NewsGoogle News·17 Aug · 4w ago
Mankind Pharma Releases BSVL Share Pledge, Realignment of NCD Security Complete
NewsGoogle News·17 Aug · 4w ago
Long-term trend bearish — 200-day average falling over the past quarter
Technicals · trend·11 Sept · 2d ago
1 other SEBI-registered advisor has an active long-term SELL call on this stock
Advisor consensus · same horizon·31 Jul · 1mo ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.